NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line ...
Galectin Therapeutics Inc. (NASDAQ:GALT), a pharmaceutical company focused on the development of treatments for fibrotic disease and cancer with a market capitalization of $76.57 million, concluded ...
Hosted on MSN1mon
Galectin drops as trial for lead asset fails in MASHGalectin Therapeutics (NASDAQ:GALT) lost ~25% in the premarket on Friday after its NAVIGATE clinical trial for lead candidate belapectin failed to reach the main goal in patients with liver ...
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based ...
Geneos Wealth Management Inc. raised its stake in Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) by 10.2% in the 4th ...
Latest data shows the largest indicative borrow rate increases among liquid option names include: Galectin Therapeutics (GALT) 64.20% +3.11, ...
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs ...
Galectin Therapeutics Inc. (NASDAQ ... the company currently maintains a weak financial health score of 1.51, reflecting ongoing operational challenges. During the meeting, shareholders elected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback